▶ IPA / CJC-1295 · SUBTOPIC · DOSING LITERATURE
IPA / CJC-1295 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of IPA / CJC-1295. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for IPA / CJC-1295 reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of IPA / CJC-1295.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for IPA / CJC-1295 of approximately Ipamorelin ~2 hr · CJC-1295 No DAC ~30 min. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of IPA / CJC-1295. Refer to the original publication for full protocol detail.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B (2009) reports the IPA / CJC-1295 protocol used in Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus, published in J Pharmacol Exp Ther. PMID 19289567. See the source for the protocol-level dose range, frequency, and duration. link
- Teichman SL, Neale A, Lawrence B, et al. (2006) reports the IPA / CJC-1295 protocol used in Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults, published in J Clin Endocrinol Metab. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is ipamorelin / CJC-1295?
Ipamorelin / CJC-1295 is a two-peptide research pair commonly co-administered. Ipamorelin is a selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). CJC-1295 (No DAC variant) is a stabilized GHRH(1-29) analog. The pair amplifies the GH pulse via dual-pathway activation.
▶ What is the difference between CJC-1295 with DAC and No DAC?
CJC-1295 with DAC carries a maleimidopropionic-acid (MPA) linker that covalently binds plasma albumin in vivo, extending half-life to roughly one week. CJC-1295 No DAC (also called modified GRF(1-29) or Mod GRF 1-29) lacks the MPA linker and has the same short half-life as native GHRH (~30 min). Most current research uses the No-DAC variant; the With-DAC ConjuChem trial program was halted.
▶ What is the half-life of ipamorelin?
Approximately 2 hours plasma half-life. The pulse-and-decay profile lasts roughly 3–4 hours in published pharmacokinetic studies.
▶ What is the half-life of CJC-1295 No DAC?
Approximately 30 minutes · the same as native GHRH(1-29). The stabilizing substitutions resist DPP-IV cleavage but do not add albumin tethering. Hence the need for multiple daily injections in research protocols.
▶ Side effects of ipamorelin / CJC-1295?
Most common in community-reported research protocols: mild injection-site reactions, transient hunger (ghrelin-receptor component), mild flushing, rare water retention. Safer profile than older non-selective GHS like GHRP-6.
▶ When should ipamorelin / CJC-1295 be administered in animal studies?
Typical animal-model protocols use evening administration to align with the natural largest GH pulse during slow-wave sleep. Empty-stomach administration is preferred because elevated blood glucose blunts GH response.
▶ How is ipamorelin / CJC-1295 stored?
Lyophilized: 4 °C for 24 months. Reconstituted: 2–8 °C, use within 28 days.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Sponsored Phase 2 program for ipamorelin (postoperative ileus) discontinued. CJC-1295 with-DAC ConjuChem program halted.
WADA · Both prohibited at all times under WADA Section S2. Ipamorelin in the growth-hormone-secretagogue sub-category. CJC-1295 in the GHRH-analog sub-category.
RELATED PAGES
▶ LAST UPDATED · 2026-05-19